Laboratories Line Correcting Booster Serum

No7

No7 Laboratories Line Correcting Booster Serum is one of the most clinically substantiated peptide serums available at pharmacy pricing. The formulation centers on Matrixyl 3000+, an advanced variant of the Matrixyl 3000 peptide complex (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) developed by Sederma/Croda specifically for No7's parent company, Boots/Walgreens Boots Alliance. The '+' designation indicates a higher concentration and optimized delivery vehicle compared to standard Matrixyl 3000 formulations. What sets No7 apart in the peptide skincare space is its investment in independent clinical testing. The brand has conducted multiple double-blind, placebo-controlled studies through the University of Manchester, demonstrating statistically significant wrinkle depth reduction after 8-12 weeks of use. This level of clinical evidence is unusual for a product at this price point — most peptide serums rely on supplier-provided data for the raw peptide ingredient rather than testing the finished formulation. The serum also includes a fibrous protein complex and hyaluronic acid to support the peptide's collagen-signaling activity. The texture is lightweight and fast-absorbing, designed as a booster that layers under any moisturizer. No7's approach is refreshingly clinical for a mass-market brand — focused on one well-validated peptide technology at a proven concentration rather than listing dozens of actives at unknown levels. For users who prioritize evidence-based skincare at accessible pricing, this is one of the strongest options in the peptide category.

Links to retailers are affiliate links. We may earn a commission on qualifying purchases at no extra cost to you.